AEMD - יחס חוב להיוון בספרים Aethlon Medical Inc

Aethlon Medical (AEMD) develops innovative Hemopurifier filters to cleanse blood of tumor markers and viruses. The GURU.Markets platform displays the total debt-to-book capitalization ratio, where 0.07 describes the current status of the metric. While the product helps combat sepsis and metastasis, slow regulatory approval is hindering scaling and increasing operational laboratory expenses.

Assessing the fundamental stability of Aethlon Medical (AEMD) requires an analysis of debt load relative to equity. This debt-to-equity ratio measures the degree of financial leverage by comparing total liabilities to net assets. A decrease in this ratio minimizes bankruptcy risks but may indicate stagnation. For Aethlon Medical, such a metric is critical due to the slow adoption of costly blood purification technologies. High leverage coupled with low hospital demand for the product creates a dangerous liquidity gap.